阿德福韦酯联合复方丹参滴丸治疗乙型肝炎肝硬化代偿期疗效分析  

Effect of adefovir dipivoxil combined with composite danshen pill on hepatocirrhosis

作　　者：周一鸣[1] 曹建彪[1] 范公忍[1] 

机构地区：[1]北京军区总医院全军肝病治疗中心,100700

出　　处：《临床内科杂志》2012年第4期258-260,共3页Journal of Clinical Internal Medicine

摘　　要：目的观察阿德福韦酯联合复方丹参滴丸治疗乙型肝炎肝硬化代偿期患者的疗效。方法81例乙型肝炎肝硬化代偿期患者，随机分为3组，联合治疗组给予阿德福韦酯和复方丹参滴丸，对照组给予阿德福韦酯或复方丹参滴丸治疗，疗程均为6个月，观察治疗后6个月3组患者HBV—DNA、肝功能、血小板、脾脏厚度及肝纤维化指标的变化情况。结果治疗6个月后，阿德福韦酯组和联合治疗组患者血清HBV—DNA、肝功能均较治疗前明显好转（P〈0．05），而复方丹参滴丸组患者HBV—DNA水平元明显下降（P〉0．05），仅部分肝功能指标有所好转；联合治疗组肝纤维化指标较治疗前显著改善（P〈0．05），复方丹参滴丸组患者肝纤维化指标部分改善。而阿德福韦酯组肝纤维化指标无显著性好转（P〉0．05）。结论阿德福韦酯联合复方丹参滴丸治疗能有效抑制乙肝病毒复制，改善肝功能，减轻肝纤维化。Objective To investigate the effect of adefovir dipivoxil（ADV） combined with composite danshen pill（CDP） on hepatocirrhosis with HBV. Methods 81 patients were divided into 3 groups and treated with ADV, CDP,ADV ＋ CDP for 6 months respectively. HBV-DNA, ALT, AST, ALB, HA, LN, PCIII, CIV, PLT and the thickness of spleen were detected before and after the treatment. Results At the time after treatment for 6 months, HBV-DNA, ALT, AST declined significantly in ADV group and ADV ＋ CDP group（ P 〈 0.05 ）. HBV-DNA did not declined significantly in CDP group （P 〉 0.05 ）. The level of HA, LN, PCIII, IV C decreased, PLT elevated and the thickness of spleen decreased significantly （ P 〈 0. 05 ） in ADV ＋ CDP group. But these parameters did not change significantly in ADV group（ P 〉 0.05 ）. The level of HA, IV C decreased significantly in CDP group （P 〈 0.05）. Conclusion The treatment with ADV and CDP can effectively surppress the virus replication of HBV-DNA, ameliorate inflammation and fibrosis of liver.

关 键 词：阿德福韦酯 复方丹参滴丸 肝硬化 

分 类 号：R512.62[医药卫生—内科学]